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Abstract Children with severe congenital malformations,
such as single-ventricle anomalies, have a daunting prog-
nosis. Heart transplantation would be a therapeutic option
but is restricted due to a lack of suitable donor organs and,
even in case of successful heart transplantation, lifelong
immune suppression would frequently be associated with a
number of serious side effects. As an alternative to heart
transplantation and classical cardiac reconstructive surgery,
tissue-engineered myocardium might become available to
augment hypomorphic hearts and/or provide new muscle
material for complex myocardial reconstruction. These
potential applications of tissue engineered myocardium
will, however, impose major challenges to cardiac tissue
engineers as well as heart surgeons. This review will pro-
vide an overview of available cardiac tissue-engineering
technologies, discuss limitations, and speculate on a
potential application of tissue-engineered heart muscle in
pediatric heart surgery.
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Introduction
The heart is the ﬁrst major organ that reaches functional
competence in the developing embryo and subsequently
enables blood ﬂow through the pulmonary and systemic
circulation. Its anlage can be distinguished morphologi-
cally as early as 7 days and 3 weeks after fertilization in
mice and humans, respectively [32]. Heart function can be
assessed by ultrasound shortly afterward [41, 48]. Embry-
onic heart development begins with the formation of the
cardiac crescent; this structure will eventually fuse to
establish the primitive heart tube; subsequent looping and
septation will ﬁnally lead to the conﬁguration of the four-
chambered heart [32]. These complex processes are com-
monly disrupted, leading either to premature termination of
pregnancy or congenital malformations [50]. Taken toge-
ther, 4% of developing embryos are affected. Ultimately,
structural myocardial defects are diagnosed in approxi-
mately 1% of all newborns, making heart malformations
the most common pathological congenital condition.
Life-compatible defects, such as atrial and ventricular
septum defects (ASDs and VSDs), are frequently associ-
ated with other cardiac and extracardiac malformations as
well as chromosomal abnormalities (e.g., trisomies). More
complex malformations are rare and include, for example,
hypoplastic left heart syndrome (HLHS), double inlet left
ventricle (DILV), double outlet right ventricle (DORV),
tetralogy of Fallot (TOF), and transposition of the great
arteries (TGA). Most of these congenital heart defects are
generally not compatible with life and require compre-
hensive as well as early reconstructive surgeries such as a
switch operation for TGA and staged Fontan palliation
including the Norwood procedure in single-ventricle
anomalies [15]. Especially in the latter pathology, surgical
repair is generally palliative. Heart transplantation would
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scarcity of suitable donor organs. In addition, lifelong
immune suppression often causes serious complications,
including kidney failure and malignancies. Importantly,
long-term outcome of the above-mentioned surgical inter-
ventions remains largely unknown and it would clearly be
desirable to develop alternative strategies to repair hearts
with severe congenital malformations.
One exciting but also highly controversial approach is
intrauterine reconstructive surgery [40, 53]. The interested
reader is referred to expert reviews in this ﬁeld for detailed
information on this intervention [14, 40]. Alternatively,
biological repair using tissue-engineered myocardium
might become an option. It will, however, require the
generation of functionally competent heart muscle of suf-
ﬁcient size and with in vitro as well as in vivo growth
potential.
Several tissue-engineering technologies are already
available, enabling the generation of contractile heart
muscle in the lab [58]. Moreover, proof-of-concept for an
in vivo application of tissue-engineered myocardium to
remuscularize a failing heart has already been provided in a
rodent model of myocardial infarction [59]. It would,
nevertheless, be pretentious to claim that cardiac muscle
engineering is on the verge to clinical exploitation. Further
reﬁnements to eventually generate force-developing human
heart muscle, to provide grafts of relevant size, and to
control immunological issues will be necessary to advance
the ﬁeld. This review will discuss the state-of-the-art in
myocardial tissue engineering, its limitations, and potential
applications in pediatric heart surgery.
State-of-the-Art in Cardiac Tissue Engineering
The ultimate goal in therapeutic cardiac tissue engineering
is to generate biocompatible, nonimmunogenic heart
muscle with morphological and functional properties of
natural myocardium. To this end, at least four distin-
guishable tissue engineering modalities have been
established over the past 15 years (reviewed in [11, 58];
Fig. 1). These include the following: (1) the bioengineer-
ing approach, involving seeding of heart cells on
preformed biocompatible scaffolds [4, 5, 27, 29]; (2) the
biological assembly approach, utilizing hydrogels to entrap
heart cells and support their intrinsic capacity to organize
into a cardiac syncytium [10, 56, 57]; (3) the cell sheet
approach, using a unique technique to detach and serially
stack monolayer cell cultures to form contractile heart
tissue sandwiches [46]; (4) the decellularization–recellu-
larization approach, taking advantage of the ability to strip
tissues of all cellular components but at the same time
retain their extracellular matrix structure to be used as a
reseeding substrate for heart or cardiogenic stem cells [39].
In addition to the mentioned techniques, other modalities,
such as the microtissue approach [21], have been devel-
oped and might indeed provide therapeutic tissue
structures. This review will, however, focus only on tissue-
engineering modalities enabling the generation of force-
generating heart muscle on a macroscopic scale:
(1) The bioengineering approach utilizes preformed
scaffolds, which are either chemically engineered,
such as polylactic acid (PLA), polyglycolic acid
(PGA), and polyglycerol sebacate (PGS) [4, 5, 9], or
derived from biological sources, such as collagen/
gelatin from tendon, alginates from seaweed, and silk
from silkworms or spiders [27, 30, 42], and subse-
quently processed to generate sponges or meshes with
various pore sizes. Cells are eventually seeded onto
these scaffolds and cultured in a three-dimensional
(3D) format. Importantly, most of the above-men-
tioned materials, with collagen and silk being
exceptions, do not support cardiomyocyte attachment
or growth in an optimal way. In addition, limited
diffusion and, thus, oxygen and nutrient supply have
been main caveats of the bioengineering approach.
Moreover, synthetic polymers commonly have unfa-
vorable degradation properties (e.g., the acidiﬁcation
of surrounding tissue in the case of PLA and PGA)
and cause inﬂammatory responses [52]. This is
acceptable or even desirable if the above-mentioned
materials are used as suture material, but it is
unacceptable if the materials are used as tissue
scaffolds in vivo. To overcome this limitation, one
might opt to degrade the respective materials before
implantation. From the engineering and regulatory
point of view, the above-mentioned (bio-)materials
would be advantageous because its components are
fully chemically deﬁned and have already been
approved (e.g., PLA, PGA, alginate, collagen/gelatin
sponges) by the US Food and Drug Administration
(FDA).
(2) The biological assembly approach takes advantage of
the intrinsic propensity of cardiomyocytes to generate
‘‘cardiac microtissues’’ if cultured at a high cell
density in suspension [1, 21, 22, 34]. Suspending cells
in casting molds containing mixtures of extracellular
matrix material, such as collagen, laminin, and
ﬁbronectin [10, 36, 56, 57], or naturally occurring
products from blood, such as ﬁbrin [19], supports
self-aggregation in a deﬁned 3D environment. Expos-
ing the developing tissues to biophysical stimuli, such
as mechanical strain and electrical stimulation [12,
42], can further be used to guide cardiac tissue
formation and will eventually yield strongly
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contrast to the bioengineering approach, the shape
and size of forming tissues are not governed by the
matrix material itself, but by the casting molds
utilized for initial tissue reconstitution. Although
diffusion is also a limitation of the biological
assembly approach, it appears that hydrogels enable
better oxygen and nutrient transport as compared to
preformed matrixes. This might be the reason why
tissue formation in, for example, engineered heart
tissue (EHT) is not restricted to outer layers of the
collagen hydrogel-culture format [57]. Instead, mus-
cle within EHTs forms a delicate 3D network,
composed of 20–200-lm-thick muscle bundles
(Fig. 2). Importantly, single-muscle units generated
by the biological assembly approach might be fused
to form large tissue constructs [36]. This property
might in principle even be exploited to generate
clinical-scale tissue constructs of various geometries.
(3) The cell sheet approach is based on temperature-
controlled release of cell monolayers from PIPAAm
(polyisopropylacrylamide)-coated culture dishes [38].
PIPAAm has unique hydrophobic or hydrophilic
properties depending on the environmental tempera-
ture. Physiological temperatures (37C) facilitate cell
attachment, whereas low temperatures (20C) render
the polymeric surface hydrophilic and consequently
lead to rapid detachment of cell monolayers. Impor-
tantly, this detachment procedure does not disturb
cell–cell contacts within the monolayer and appar-
ently maintains all cell surface structures. This might
explain why cell sheets can rapidly attach and
establish electrical contacts to each other [18, 47]a s
well as to underlying myocardium if applied in vivo
[31]. Yet, the cell sheet approach is also diffusion
limited. This becomes apparent at a monolayer-stack
diameter of *100 lm (four to six layers) [46].
Employing sequential grafting of thin layers on top of
Leor et al.
Radisic et al.
Naito et al.
Zimmermann et al. Shimizu et al.
Huang et al. Ott et al.
Biological assembly Cell sheet De-/Recellularization Bioengineering
Fig. 1 Tissue engineering modalities enabling the generation of large
macroscopically contracting tissue constructs: (1) bioengineering
approach [27, 42], (2) biological assembly approach [36, 57], (3) cell
sheet approach [19, 46], and (4) decellularization–recellularization
approach [39]
Fig. 2 Muscle formation in
EHT. Actin staining (white in
[a], green in [b]) denotes the
formation of a dense network of
muscle strands, which might in
some cases reach a diameter of
up to 200 lm. Images from [57]
(a) and [36]( b). (Color ﬁgure
online)
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compact vascularized tissues with a diameter of at
least 1 mm in vivo [47].
(4) The decellularization-recellularization approach
employs tenside (SDS: sodium dodecyl sulfate) and
DNase treatment to dispose of all potentially immu-
nogeneic structures of the heart and subsequent
reseeding of the remaining extracellular matrix
(ECM) with cells either by direct injection into the
‘‘naked’’ ECM or transfusion through spared vascular
channels [39]. The latter approach appears better
suited to reestablish a homogenous musculature in the
heart but would require that cells migrate into the
heart’s ECM and form a continuous functional
syncytium. Future studies will have to provide
evidence that this can indeed be achieved and that
the resulting hearts can be transplanted and perform
as desired in vivo. To this end, ﬁrst short-term data
from a heterotopic heart transplantation model are
encouraging [39].
Limitations
Myocardial tissue engineering still has to go a long way in
order to be translated into a clinically exploitable treatment
modality, and it is difﬁcult to predict when or even whether
it will ever reach its proposed potential. Yet, important
recent clinical studies have demonstrated that tissue-engi-
neered products might indeed be applicable to offer
mechanical and/or paracrine support to failing hearts ([7];
Sawa et al., personal communication). These studies could
clearly be considered pivotal because they describe a ﬁrst-
in-man application of the bioengineering [7] and cell sheet
approach (Sawa et al., personal communication). Yet, the
patient number in both of these studies was minimal;
therefore, carefully designed follow-up studies need to be
conducted to identify the potential of tissue-engineered
products in heart repair. However, unearthing the ultimate
potential of myocardial tissue engineering will likely
require the utilization of contractile muscle elements to
remuscularize a failing heart and thereby also functionally
compensate for a loss of cardiac muscle. Force-generating
myocardium will have to be engineered in vitro and
seamlessly integrated in diseased hearts to achieve this
goal. Importantly, the potential of electrical and structural
integration of heart cells into an allogeneic recipient has
already been demonstrated by multiple groups [13, 44, 59]
and it is likely that electrical integration will not be an issue
if demarcation of implants by scar formation can be con-
trolled [43]. Hence, the most pertinent limitations include
(1) the applicability of human heart cells in cardiac tissue
engineering, (2) overcoming size limitations, and (3) pro-
viding fully biocompatible tissue-engineered muscle. The
following list provides a discussion of these issues:
(1) Human heart cells can be isolated from biopsy and
autopsy material. These cells will, however, not be
suitable for myocardial tissue engineering given their
limited number, lack of cell cycle activity, and
inability to reestablish a functional syncytium once
they have been dispersed into single-cell suspensions.
Consequently, cardiogenic stem cells will have to be
exploited. Adult stem cells from the bone marrow do
not harbor the capacity to generate the substantial
amount of myocytes needed for complex myocardial
reconstitution [3, 35, 37]. In contrast, embryonic stem
cells can, in principle, provide cardiomyocytes in
adequate numbers [55]. In addition, embryonic stem-
cell-derived myocytes are still capable of developing
into complex functional syncytia [20] and, only
recently, the use of embryonic stem-cell-derived
cardiomyocytes was demonstrated in myocardial
tissue engineering [6, 17]. Collectively, these data
provide strong evidence that embryonic stem cells
might be an appropriate cell source for clinical-scale
myocardial tissue engineering. However, cardiomyo-
cyte yield from embryonic stem cells is generally low
(1–5%; [23]) and scalability will, consequently, be an
important issue to generate relevant cardiomyocyte
numbers and eventually ‘‘force-generating’’ human
myocardium. The later goal has, despite two recent
reports using embryonic stem-cell-derived myocytes
in a 3D culture format [6, 45], not been achieved, but
it is likely that hydrogel-cultures will be instrumental
to generate such tissues [60]. Similarly, nonembry-
onic pluripotent stem cells, including induced
pluripotent stem cells [49], spermatogonial stem cells
[16], and parthenogenetic stem cells [51], will be
exploitable in cardiac tissue engineering. These cell
types will, on the one hand, not require cell harvest
from an early embryo and might, in addition, be
suitable for the generation of autologous cells;
however, other ethically controversial issues remain,
including the need for genetic manipulations in the
induced pluripotent stem-cell-based technology and
the risk of in vitro mutagenesis and teratoma forma-
tion after an in vivo application.
(2) Itwillbeessentialtogenerateandimplantthickmuscle
tissuestoachievemeaningfulcontractilesupportinthe
setting of heart failure, to adequately replace scarred
heart tissue in individuals with myocardial infarction,
or to repair tissue deﬁciencies in pediatric hearts. The
need for continuous oxygen and nutrient supply to
metabolically highly active myocardium is a key issue
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cardium can already be reconstituted in vivo with a
diameter of up to 1 mm [47, 59], this would likely be
insufﬁcient to impart a clinically relevant effect. In
vivo physiological muscle diameters of at least 10 mm
need to be matched. To achieve this goal, ‘‘in vitro
vascularization’’ might be a prerequisite. It is unlikely
that this will be achieved by simply adding endothelial
cells or smooth muscle cells to a tissue reconstitution
mixture, although it has been clearly documented that
nonmyocytes will have beneﬁcial effects, which
include the formation of primitive capillary structures
in tissue-engineered heart muscle [28, 36, 57]. This
will, however, not likely be sufﬁcient to provide
immediate circulatory support to large engineered
tissue grafts in vivo. To overcome this limitation,
vascularized myocardial tissues could be generated
in vivo either by seeding cardiogenic cells in prev-
ascularized chambers [33] or by introducing a macro-
vasculature with deﬁned inﬂow and outﬂow to enable
surgical anastomoses to, for example, the coronary
arteries [24].
(3) Tissue-engineered myocardium would ideally be gen-
erated from biocompatible and autologous material.
Biocompatible matrix materials are commonly avail-
able(e.g.,collagen).Unfortunately,autologouscardio-
geneic cells are not readily available. Adult stem cells
from the blood or bone marrow would be logistically
idealbutdonothavetheintrinsiccapacitytogiveriseto
cardiomyocytes of sufﬁcient quality and quantity [2].
In contrast, embryonic stem cells can give rise to bona
ﬁdecardiomyocytes[8,20,54],whichwould,however,
elicit an immune response in an allogenic recipient
[25]. Alternatively, induced pluripotent [49], sper-
matogonial [16], and parthenogenetic [51] stem cells
could be applied autologously. These cell types appear
to have the most characteristics of embryonic stem
cells, including the capacity to give rise to cardiomyo-
cytes.Thismakesthemanattractivesourceforcardiac-
muscle-engineering and other tissue-engineering
applications. Finally, the necessity for an autologous
application needs to be carefully considered, given the
time needed to generate a therapeutic autologous cell
pool (weeks to months) and, subsequently, an autolo-
gous tissue (takes roughly 7 days when embryonic
stem cells are used to generate EHTs; our own
unpublished data). Having this in mind, it might be
worthwhile to consider cell banking for tissue-engi-
neeringapplications.Inthisscenario,cellswithdeﬁned
immunological features would be banked to be
matched with an allogeneic recipient. Under these
circumstances, it would be likely that induction of
differentiationfollowedbycardiacmuscleengineering
could be achieved within 2–3 weeks. This time frame
appears clinically acceptable. In addition, palliative
procedurescouldbridgethegapuntiltissue-engineered
products would be ready for a clinical application.
Time-frame concerns for early postnatal heart surgery
might also be irrelevant if immune-matched heart
tissue could be generated to be available at birth.
Application of Tissue-Engineered Myocardium in
Pediatric Heart Surgery
Tissue-engineered-based myocardial repair hasbeenmainly
discussed for adult patients, being affected either by global
heart failure or localized myocardial damage (e.g., after a
myocardial infarct) [58]. Minimal myocardial reconstruc-
tion, as sometimes required in isolated ASDs and VSDs,
might not be ideal conditions for biological repair with tis-
sue-engineered myocardium. However, children with
hypomorphicventriclesasobservedinHLHSorDILVcould
potentially beneﬁt from an augmentation of the affected
ventricle or septation of a single ventricle with a fully bio-
logical contractile patch (Fig. 3). These procedures would
likelyrequirefurtherinﬂowandoutﬂowtrackreconstruction
aswellasseamlesselectricalandstructuralintegrationofthe
biologicalgraftintotherecipientheart.Itwould,inaddition,
be likely that such an intervention would have to be paral-
leled by electrical synchronization of the implant and the
recipient heart. Given the prognosis of children with sin-
gle-ventricle anomalies and the lack of organ donations for
HLHS
RV
DILV
RV LV
RV
LV SV
Fig. 3 Schematic drawings of potential applications of tissue-engi-
neered myocardium (gray) for left ventricular augmentation (top)o r
single-ventricle septation (bottom) in children with HLHS or DILV,
respectively. RV: right ventricle; LV: left ventricle; SV: single
ventricle
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123heart transplantation, this additional intervention might be
acceptable. Another issue will be to perform the appropriate
preclinicalandclinicalstudiestoassesssafetyandfeasibility
as well as efﬁcacy of such an intervention. Major safety
concerns will also depend on the utilized cell type. Espe-
cially in the case of embryonic stem cells or non-embryonic
pluripotent stem cells and derivatives, teratoma formation
cannotberuledout[26].Thisissuehas,however,notstopped
theFDAfromgrantingapprovaltoaﬁrst-in-humantrialwith
embryonic stem-cell-derived oligodendrocytes in spinal
cord injury repair (GRNOPC1, Geron Corp.).
Conclusions
Organ repair strategies utilizing cell products are rapidly
evolving. Adult stem cells from the bone marrow will be
tested shortly in a pivotal phase III trial for efﬁcacy
(TOPCARE-AMI). Results from this study are expected in
2011 (Zeiher et al., personal communication). Derivatives
from embryonic stem cells will enter a ﬁrst clinical trial
shortly. The outcome of the latter will be of paramount
importance not only for cell implantation studies but also
for the tissue engineering ﬁeld. In particular, cardiac tissue
engineering will depend crucially on the availability of
stem cells capable of providing cardiomyocytes in large
numbers. To this end, embryonic stem cells or nonem-
bryonic pluripotent stem cells, including induced
pluripotent stem cells, spermatogonial stem cells, and
parthenogenetic stem cells, appear to be instrumental. If
safety can be demonstrated for embryonic stem cell
derivatives in spinal cord injury, it will be logical to also
advance tissue-engineering technologies that utilize
embryonic stem cells or nonembryonic alternatives into
large animals and subsequently human trials.
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